ClinicalTrials.gg
Not yet recruitingNCT07830563Updated Sep 21, 2026

Evaluating the Safety and Effects of AMP-101 in People With DOK7 Congenital Myasthenia Syndrome

A Phase 1 interventional study of AMP-101 in Congenital Myasthenia Syndrome, sponsored by Amplo Biotechnology. Not yet recruiting. Open to participants aged 7 Years and older. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Amplo Biotechnology · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
7 Years and older
Sex
All
01

Study summary

This study is evaluating the safety and potential effects of AMP-101 in people with DOK7 Congenital Myasthenia Syndrome (CMS). Participants will receive a single dose of the study treatment and will be monitored to assess their health and response to treatment. Approximately 4 participants are expected to take part in the study.

02

Conditions studied

  • Congenital Myasthenia Syndrome
03

In context

Lead sponsor

This is the only study on the registry with Amplo Biotechnology as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
7 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A diagnosis of moderate to severe DOK7 CMS as defined by:

    1. genetic mutation analysis,
    2. demonstrated clinical findings such as limb girdle muscle weakness,
    3. exercise intolerance.
  • Is willing to discontinue drugs known to worsen symptoms in DOK7 CMS patients such as 3,4-diaminopyridine (3,4-DAP) and pyridostigmine at least 1 month prior to Day 1.
  • If being treated with oral salbutamol, is clinically stable, and plans to remain on the same dose for the duration of the study through to EoS (approximately 6 months) - unless a change in dose is medically indicated at the discretion of the PI or designee.
  • If discontinuing oral salbutamol, is clinically stable, and has been off the medication for at least 1 month prior to Day 1 - unless a change in dose is clinically indicated at the discretion of the PI or designee.
  • Not pregnant or breastfeeding, or willing to cease breastfeeding.

Exclusion criteria

Exclusion Criteria:

  • Active infections including Epstein-Barr virus (EBV), cytomegalovirus (CMV), positive test for antibody (HCV), surface antigen (HBsAg), (HIV) antibody.
  • Have required oral or systemic within the last 14 days prior to Screening.
  • Rh74 AAV capsid binding antibody titers > 1:100 as determined by ELISA immunoassay.
  • count below the lower limit of normal (LLN) at Screening.
  • Have received other gene transfer/gene therapy agents.
  • liver dysfunction, including significant hepatic fibrosis, liver cirrhosis of any etiology identified by liver ultrasound or other imaging modalities, portal hypertension, or a history of hepatic .
  • Current or history of clinically significant respiratory failure, including the requirement for long-term supplemental oxygen therapy, non-invasive ventilation, mechanical ventilation, or other evidence of severe respiratory impairment, as determined by medical history, physical examination, or pulmonary function assessment.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (estimated)

Study arms

  • Experimental
    AMP-101

    Drug: AMP-101

Interventions

  • DrugAMP-101

    Route of Administration: intravenous infusion Unit Dose Strength: 5.02 x10\^13 Vg/ml in a volume of 1 mL/vial

06

What researchers measure

Primary outcomes

  1. Incidence of TEAEs.

    Time frame: From Screening to Day 180 (EOT visit)

  2. Incidence of AESIs (Adverse events of special interest)

    Time frame: From Screening to Day 180 (EOT visit)

  3. Incidence of SAEs.

    Time frame: From Screening to Day 180 (EOT visit)

  4. Number of participants with abnormal vital signs

    Time frame: From Screening to Day 180 (EOT visit)

  5. Number of participants with abnormal ECG readings

    Time frame: From Screening to Day 180 (EOT visit)

  6. Number of participants with abnormal Laboratory findings

    Time frame: From Screening to Day 180 (EOT visit)

  7. Incidence of anti-AAV antibodies.

    Time frame: Day 28, Day 63, Day 90 and Day 180 (EOT visit)

Secondary outcomes

  1. Changes in Modified QMGS (Quantitative Myasthenia Gravis Score) from baseline

    This will be assessed by a Test comprising 13 physician-evaluate items endorsed by Myasthenia Gravis Foundation of America (MGFA).

    Time frame: Days 1, 28, 56,90 and Day 180 (EOT visit)

  2. Changes in MG-ADL (Myasthenia Gravis Activities of Daily Living Scale) score from baseline

    This will be assessed by an 8-item patient-reported scale containing 2 items of daily life activities, and 6 items reflecting MG symptoms. The tests assess functional impact of MG using 0-3 scaling system, with scoring range from 0 to 24

    Time frame: Days 1, 28, 56,90 and Day 180 (EOT visit)

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Oct 2028, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2026
First posted
Sep 21, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Oct 1, 2028
CompletionEst.
Oct 1, 2031
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07830563
Lead sponsor
Amplo Biotechnology
Responsible party
Sponsor
First posted
Sep 21, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Oct 1, 2028 (estimated)
Completion
Oct 1, 2031 (estimated)
Last update
Sep 21, 2026

Study contacts

Patricio Sepulveda
Contact
commdev@amplobiotechnology.com
858-241-6835

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion